GRANULATORS FOR PHARMACEUTICAL MARKET ANALYSIS

Granulators For Pharmaceutical Market, by Product Type (Single Pot Granulators, High Sheer Granulators, Fluid Bed Granulators, Rapid Mixer Granulators, Oscillating Granulators, and Others), By Granulation Mechanism (Dry Granulators, Wet Granulators, and Mixed Granulators), By End User (Pharmaceutical Manufacturing Companies, Contract Manufacturing Organizations, Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Mar 2020
Code : CMI1649
Pages :186
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Global Pharmaceutical Granulators Market- Regional Insights

On the basis of region, the global pharmaceutical granulators market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the most lucrative region for growth of the pharmaceutical granulators market owing to presence of pharmaceutical manufacturers in the region with huge production plants that involve mass manufacturing and development of oral pharmaceutical drugs.

Moreover, expansion of production facilities by existing pharmaceutical players and introduction of new production plants by players in the pharmaceutical industry are also contributing to growth of the market in North America. For instance, in March 2017, Apotex, Inc., a Canadian pharmaceutical company, announced an investment of US$ 184 million for expansion of its advanced manufacturing and R&D facility in Florida. Additionally, according to a survey report published by the USFDA in 2016, the top 15 pharmaceutical companies in the U.S. invested an estimated 20.5% of their pharmaceutical sales in research and development of new drugs.

Asia Pacific pharmaceutical granulators market revenue is expected to witness significant growth due to increasing investments by leading pharmaceutical players in expansion of their production units in the region. For instance, in March 2018, Merck KGaA invested US$ 47 million for expansion of manufacturing plants in South Korea and India to develop biologics and other pharmaceutical drugs.